View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 25, 2017updated 26 Oct 2017 11:11am

Pharmexcil forecasts India’s generics exports growing at 22% per year

An update provided by the India Brand Equity foundation (IBEF) and the Pharmaceuticals Export Promotion Council (PHARMEXCIL) has shown that the country’s generic exports are expanding by approximately 22% per year.

An update provided by the India Brand Equity foundation (IBEF) and the Pharmaceuticals Export Promotion Council (PHARMEXCIL) has shown that the country’s generic exports are expanding by approximately 22% per year.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

As per the data, India’s branded generic sector boasts a value of $12bn accounting to 98% of the marketplace.

The exports cover more than 60,000 brands and 60 therapeutic classes and form about 20-22% of the world’s production.

With pharmaceutical exports reported to have expanded to $16.84bn in 2016-17, the country supplied 34% of its total exports to the US and 15% to European Union (EU).

“Moreover, government policies are directed at increasing infrastructure facilities to help enable manufacturing to reach its highest potential, with pharma exports expected to reach $20bn by 2020.”

Pharmexcil director general Ravi Udaya Bhaskar said: “A key driver for this growth is India’s extensive product portfolio, which provides the capability to manage and treat any ATC (anatomical therapy classification) – to the same quality as the innovators – at highly affordable costs.”

The country is reported to have contributed up to 50% of new drug master files (DMFs) per year over the past ten years and supported numerous abbreviated new drug applications (ANDAs) filed by various US and EU firms.

Additionally, India has achieved 30%-50% of the total certificate of suitability (CEPs) between 2013 and this year and is said to be the first country to file generic drugs in both the US and the EU.

Bhaskar further noted: “Moreover, government policies are directed at increasing infrastructure facilities to help enable manufacturing to reach its highest potential, with pharma exports expected to reach $20bn by 2020.”


Image: New update estimates India’s generic exports to be about $20bn by 2020. Photo: courtesy of Serge Bertasius Photography/FreeDigitalPhotos.net.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology